Haemonetics Corporation (HAE)

Return on equity (ROE)

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Net income (ttm)	US$ in thousands	117,558	126,574	128,277	136,566	115,401	95,759	86,047	67,706	43,375	22,593	31,243	64,488	79,469	108,134	106,147	95,532	76,526	79,737	41,363	22,603
Total stockholders’ equity	US$ in thousands	959,959	943,319	893,660	864,616	817,997	775,979	729,009	770,423	749,424	730,775	698,549	677,080	731,670	719,152	667,923	608,569	587,109	574,580	583,754	590,966
ROE		12.25%	13.42%	14.35%	15.79%	14.11%	12.34%	11.80%	8.79%	5.79%	3.09%	4.47%	9.52%	10.86%	15.04%	15.89%	15.70%	13.03%	13.88%	7.09%	3.82%

March 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $117,558K ÷ $959,959K
= 12.25%

Haemonetics Corporation's return on equity (ROE) has shown fluctuations over the past few quarters. The ROE has generally been trending upwards from the end of 2020 to the middle of 2023, reaching a peak of 15.89% in September 2020. However, there was a slight decrease in ROE in the most recent quarter, dropping to 12.25%.

Overall, the ROE for Haemonetics Corporation has been relatively healthy, consistently above 10% in most periods. This indicates that the company has been generating a favorable return on shareholders' equity. It is essential to monitor these fluctuations in ROE to assess the company's efficiency in utilizing its equity to generate profits for its shareholders.